NASDAQ:MENS Jyong Biotech Q4 2025 Earnings Results & Report $1.80 +0.03 (+1.69%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.02 (+1.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jyong Biotech reported Q4 2025 earnings on May 15, 2026. The company reported EPS of -$0.02. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMay 15, 2026TimeBefore Market OpensConference Call7:00 AM ET Jyong Biotech EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AJyong Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) Jyong Biotech Q4 2025 Earnings FAQ Did Jyong Biotech beat earnings estimates for Q4 2025? Jyong Biotech (NASDAQ:MENS) reported earnings of -$0.02 per share for Q4 2025. The report was announced on Friday, May 15, 2026. Jyong Biotech Earnings HeadlinesJyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, CaliforniaOctober 21, 2026 | globenewswire.comJyong Biotech Ltd. Plans to Establish Potential New Manufacturing Facility and U.S. Operations Center in TexasOctober 15, 2026 | marketscreener.comMThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 17 at 1:00 AM | Porter & Company (Ad)Jyong Biotech Targets BPH/LUTS Market With Proposed U.S. Manufacturing FacilityOctober 15, 2026 | rttnews.comJyong Biotech Plans Potential Texas Manufacturing Facility and U.S. Operations CenterOctober 15, 2026 | quiverquant.comQJyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug CandidatesOctober 15, 2026 | globenewswire.comSee More Jyong Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jyong Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jyong Biotech and other key companies, straight to your email. Email Address About Jyong BiotechJyong Biotech (NASDAQ:MENS) is a clinical-stage biopharmaceutical company based in Taiwan that develops treatments for urological diseases. Its research focuses on botanical drug candidates, including therapies for conditions affecting the prostate and urinary system. The company’s pipeline includes MCS-2, a botanical drug candidate being developed for benign prostatic hyperplasia, a noncancerous enlargement of the prostate. Jyong Biotech is also developing other candidates for urological conditions. Jyong Biotech was established in Taiwan and conducts drug development activities there. Its focus is on advancing its pipeline through clinical development; its candidates are investigational and are not established treatments.View Jyong Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.